The ability of ID3 to contribute to the resistance to MEKi in both NRAS-mutant (WM4265.2, M93–047) and BRAF-mutant (1205Lu, WM983B) melanomas suggested that it might be a good therapeutic target for melanoma. Here, NRAS is linked to melanoma.